ANL vs. ABUS, FULC, LRMR, PEPG, TVTX, KRRO, TRDA, NGNE, TBPH, and ALT
Should you be buying Adlai Nortye stock or one of its competitors? The main competitors of Adlai Nortye include Arbutus Biopharma (ABUS), Fulcrum Therapeutics (FULC), Larimar Therapeutics (LRMR), PepGen (PEPG), Travere Therapeutics (TVTX), Korro Bio (KRRO), Entrada Therapeutics (TRDA), Neurogene (NGNE), Theravance Biopharma (TBPH), and Altimmune (ALT). These companies are all part of the "pharmaceutical preparations" industry.
Adlai Nortye (NASDAQ:ANL) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, community ranking, media sentiment, institutional ownership and profitability.
Adlai Nortye has higher earnings, but lower revenue than Arbutus Biopharma.
35.2% of Adlai Nortye shares are owned by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are owned by institutional investors. 4.0% of Arbutus Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
In the previous week, Arbutus Biopharma had 13 more articles in the media than Adlai Nortye. MarketBeat recorded 13 mentions for Arbutus Biopharma and 0 mentions for Adlai Nortye. Arbutus Biopharma's average media sentiment score of 0.29 beat Adlai Nortye's score of 0.00 indicating that Arbutus Biopharma is being referred to more favorably in the news media.
Arbutus Biopharma received 421 more outperform votes than Adlai Nortye when rated by MarketBeat users. However, 100.00% of users gave Adlai Nortye an outperform vote while only 70.83% of users gave Arbutus Biopharma an outperform vote.
Adlai Nortye currently has a consensus target price of $30.00, suggesting a potential upside of 127.27%. Arbutus Biopharma has a consensus target price of $4.33, suggesting a potential upside of 52.05%. Given Adlai Nortye's higher possible upside, research analysts plainly believe Adlai Nortye is more favorable than Arbutus Biopharma.
Adlai Nortye has a net margin of 0.00% compared to Arbutus Biopharma's net margin of -572.81%. Adlai Nortye's return on equity of 0.00% beat Arbutus Biopharma's return on equity.
Summary
Arbutus Biopharma beats Adlai Nortye on 7 of the 12 factors compared between the two stocks.
Get Adlai Nortye News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Adlai Nortye Competitors List
Related Companies and Tools
